A Preliminary Study About Unexplained Recurrent Miscarriage and Repeated Implantation Failure Patients Treated With Low-dose Lymphocyte Immunotherapy

Unexplained Recurrent Miscarriage and Recurrent Implantation Failure Clinical Trial

— immunotherapy  

Official title:

A Preliminary Study About Unexplained Recurrent Miscarriage and Repeated Implantation Failure Patients Treated With Low-dose Lymphocyte Immunotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03081325
• Other study ID #: BL2015007
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: March 8, 2017
• Last updated: April 9, 2018
• Start date: March 2015
• Est. completion date: July 20, 2017

Study information

• Verified date: April 2018
• Source: Nanjing University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Recurrent miscarriage(RM) and recurrent implantation failure (RIF) are clinical challenge for clinicians and patients who are desperate for a healthy child.The specific etiology contains chromosomal abnormalities, reproductive anatomical abnormalities, endocrine disorders, reproductive system infections, autoimmune and environmental factors. However there are still 50% to 60% RM and RIF which don't have a clear cause,mainly associated with alloimmune factors.Among various treatments,lymphocytes active immunotherapy is the most common treatment method, and its clinical efficacy is widely recognized although its action mechanism is not clear so far.

Description:

The main mechanism of active immunotherapy includes upregulating Th2-type cytokines, downregulating Th1-type cytokines, making Th1 / Th2 shift to Th2, inducing maternal serum IL-6 and sIL6R, PIBF, EGF; inducing the expression of Fas / Fasl on lymphocyte surface; increasing the proportion of CD8 + cells, Th2-type cells and CD + CD25 + Treg cells, decreasing the activity of CD56 + CD16 + NK cell and so on.The purpose of this study is to observe the treatment effects of active immunotherapy on uRM and RIF patients. What's more,we will used flow cytometry, and quantitative real-time PCR (qPCR) methods to characterize Th1、Th2 and Treg cell populations after immunotherapy,ecpecting to find out the exact molecule mechanism of immunotherapy with paternal or third party lymphocytes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 292
• Est. completion date: July 20, 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 40 Years

Eligibility

Inclusion Criteria:

• Healthy except for their history of recurrent abortions and were negative for blocking antibodies

• Willing to receive follow up

Exclusion Criteria:

• Patients with genetic impairment

• Patients with Mullerian anomaly

• Patients with hormonal deficiency

• Patients with metabolic disorder

• Patients with infectious disease

• Patients with autoimmune abnormalities

Related Conditions & MeSH terms

• Abortion, Habitual
• Abortion, Spontaneous
• Unexplained Recurrent Miscarriage and Recurrent Implantation Failure

Intervention

Procedure:
• low-dose lymphocyte immunotherapy
Peripheral venous blood (PBMCs) was drawn from the husbands of uRM and RIF patients and then the PBMCs were resuspended and administered intradermally to uRM and RIF patients 3 times at 3-week intervals. Once conceived, the uRM and RIF patients undergo 2 rounds of treatment at 8-week intervals.

Locations

Country	Name	City	State
China	Reproductive Medicine Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Nanjing University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	T cell proportion	We use flow cytometry to detecte peripheral blood Th1?Th2 and Treg cells of uRM and RIF patients before and after low-dose lymphocyte immunotherapy to see if the immunotherapy have treatment effect on Th1/Th2/Treg paradigm disorder	1 year
Primary	Abortion rate	We undergo follow-up of all the uRM patients to see the abortion rate (miscarriage was confirmed by ultrasound before the 20th week of gestation) after lymphocyte immunotherapy	1 year
Primary	IVF outcomes	We observed the the implantation rate, clinical pregnancy rate, and ongoing pregnancy rate of RIF patients after low-dose lymphocyte immunotherapy	1 year